|Recombinant Human C-X-C Motif Chemokine 2/CXCL2|
|Description||Recombinant Human C-X-C Motif Chemokine 2/CXCL2 is produced with our E. coli expression system. The target protein is expressed with sequence (Thr39-Asn107) of Human CXCL2.|
|Names||C-X-C Motif Chemokine 2, Growth-Regulated Protein Beta, Gro-Beta, Macrophage Inflammatory Protein 2-Alpha, MIP2-Alpha, CXCL2, GRO2, GROB, MIP2A, SCYB2|
|Formulation||Lyophilized from a 0.2 μM filtered solution of 20mM Tris-HCl, 400mM NaCl, pH 8.5|
|Shipping||The product is shipped at ambient temperature.|
|Reconstitution||Always centrifuge tubes before opening. Do not mix by vortex or pipetting.|
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in 1X PBS.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
|Storage||Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.|
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
|Purity||Greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE.|
|Endotoxin||Less than 0.1 ng/μg (1 IEU/μg).|
|Amino Acid Sequence|
|Background||Chemokine (C-X-C Motif) Ligand 2 (CXCL2) is a small secreted cytokine which belongs to the CXC chemokine family. CXCL2 is 90% identical in amino acid sequence as a related chemokine, CXCL1. CXCL2/MIP2-alpha is secreted by monocytes and macrophages and is chemotactic for polymorphonuclear leukocytes and hematopoietic stem cells. The gene for CXCL2 is located on human chromosome 4 in a cluster of other CXC chemokines. CXCL2 mobilizes cells by interacting with a cell surface chemokine receptor called CXCR2. CXCL2/MIP2-alpha has been known to regulate immune functions mainly by chemo-attracting neutrophils. It is produced by activated monocytes and neutrophils and expressed at sites of inflammation. CXCL2 is a hematoregulatory chemokine, which suppresses hematopoietic progenitor cell proliferation. CXCL2 can be induced by receptor activator of NF-kappaB ligand, the osteoclast (OC) differentiation factor, through JNK and NF-kappaB signaling pathways in OC precursor cells. CXCL2 in turn enhanced the proliferation of OC precursor cells of bone marrow-derived macrophages (BMMs) through the activation of ERK. Knockdown of CXCL2 inhibited both the proliferation of and the ERK activation in BMMs. During osteoclastogenesis CXCL2 stimulated the adhesion and the migration of BMMs. CXCL2 is a novel therapeutic target for inflammatory bone destructive diseases.|